PharmaLive: Redpoint Bio to Present at the 19th Annual Wall Street Analyst Conference
September 3rd, 2008 | by admin |
EWING, N.J.–(BUSINESS WIRE)–Sep 3, 2008 - Redpoint Bio Corporation (OTCBB: RPBC), a company leveraging recent discoveries in the molecular biology of taste to discover and develop novel taste modulators for the food, beverage and pharmaceutical industries, today announced that Chief Executive Officer, Dr. Ray Salemme will present an overview of the Company at the 19th Annual Wall Street Analyst Conference in New York on Wednesday, September 10, 2008 at 12:30pm Eastern Time at The University Club.
Interested parties may access the webcast at http://www.wsw.com/webcast/wsaf7/rpbc.ob/, or on the Company’s website at http://www.redpointbio.com.
About Redpoint Bio
Redpoint Bio is leveraging recent discoveries in the molecular biology of taste to discover and develop novel taste modulators for the food, beverage and pharmaceutical industries. Redpoint Bio’s food and beverage program is focused on identifying novel compounds that improve the tastes of existing ingredients and enable the development of better-tasting and more healthful foods and beverages. The pharmaceutical program uses a biochemical approach aimed at suppressing the bitterness of medicines, which has the potential to expand the range of formulation options and increase patient compliance. For more information, please visit the Company’s website at www.redpointbio.com.
Safe Harbor Statement
In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The Company’s performance and financial results could differ materially from those reflected in these forward-looking statements due to, among other factors, uncertainty inherent in the discovery phase of technological development, any efforts by third parties to invalidate or limit any patents, the marketplace acceptance of its products, the decisions of regulatory authorities, the results of clinical trials and general financial, economic, regulatory and political conditions affecting the food, biotechnology and pharmaceutical industries generally. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The Company undertakes no obligation to update publicly any forward-looking statement.
Contact
Redpoint Bio:
Scott Horvitz, 609-637-9700, ext. 207
Chief Financial Officer
shorvitz@redpointbio.com
or
Investor Relations Firms:
Rx Communications Group
Paula Schwartz (investors): 917-322-2216
Eric Goldman (media): 917-322-2563
or
Redington Inc.
Thomas Redington (investors): 212-926-1733
Stumble it!
